Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBT6050 + HER2-directed therapies in advanced HER2+ cancers
NCT05091528Phase 2Terminated
- Sponsor
- Silverback Therapeutics
- Start
- Feb 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of pertuzumab zuvotolimod in HER2-positive breast cancer, Gastric cancer (HER2-positive), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), sponsored by Silverback Therapeutics. Started Feb 2022; status: terminated.
02
Drugs
pertuzumab zuvotolimod
03
Conditions
HER2-positive breast cancerGastric cancer (HER2-positive)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05091528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05091528.